Publications

Effect of evidence updates on key determinants of measles vaccination impact: a DynaMICE modelling study in ten high-burden countries.

FU, H; ABBAS, K; KLEPAC, P; VAN ZANDVOORT, K; TANVIR, H; Portnoy, A; JIT, M;

2021

BMC Medicine, (2021).19 1 10.1186/s12916-021-02157-4.

COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.

PEARSON, CA B; BOZZANI, F; PROCTER, SR; DAVIES, NG; Huda, M; JENSEN, HT; KEOGH-BROWN, M; Khalid, M; SWEENEY, S; TORRES-RUEDA, S; CHiL COVID-19 Working Group,; CMMID COVID-19 Working Group,; EGGO, RM; VASSALL, A; JIT, M;

2021

PLoS medicine, (2021).18 10 10.1371/journal.pmed.1003815.

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya.

Kagucia, EW; Gitonga, JN; Kalu, C; Ochomo, E; Ochieng, B; Kuya, N; Karani, A; Nyagwange, J; Karia, B; Mugo, D; Karanja, HK; Tuju, J; Mutiso, A; Maroko, H; Okubi, L; Maitha, E; Ajuck, H; Mukabi, D; Moracha, W; Bulimu, D; Andanje, N; Aman, R; Mwangangi, M; Amoth, P; Kasera, K; ... Magarini Sub-County TDA SARS-CoV-2 Serosurveillanc,

2021

Open Forum Infectious Diseases, (2021).8 7 10.1093/ofid/ofab314.

Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled tri...

Leach, AJ; MULHOLLAND, EK; Santosham, M; Torzillo, PJ; McIntyre, P; Smith-Vaughan, H; Wilson, N; Arrowsmith, B; Beissbarth, J; Chatfield, MD; Oguoma, VM; Licciardi, P; Skull, S; Andrews, R; Carapetis, J; McDonnell, J; Krause, V; Morris, PS;

2021

Vaccine: X, (2021).7, 10.1016/j.jvacx.2021.100086.

Better data for country-level TB resource allocation are urgently required.

Clarkson, MC; MCQUAID, CF; HOUBEN, RM; KRANZER, K; WHITE, RG;

2021

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, (2021).25 8 10.5588/ijtld.20.0912.

Durable natural killer cell responses after heterologous two-dose Ebola vaccination.

Wagstaffe, HR; Susannini, G; Thiébaut, R; Richert, L; Lévy, Y; Bockstal, V; Stoop, JN; Luhn, K; Douoguih, M; Riley, EM; Lacabaratz, C; GOODIER, MR;

2021

npj Vaccines, (2021).6 1 10.1038/s41541-021-00280-0.

How can early stage economic evaluation help guide research for future vaccines?.

Newall, AT; Beutels, P; Tuffaha, HW; Hall, PS; JIT, M;

2021

Vaccine, (2021).40 2 10.1016/j.vaccine.2021.11.017.

Disregarding the restrictive vial-opening policy for BCG vaccine in Guinea-Bissau: impact and cost-effectiveness for tuberculosis mortality and all-cause mortality in children aged 0-4 years.

Thysen, SM; Fisker, AB; Byberg, S; Aaby, P; Roy, P; WHITE, R; Griffiths, U; Harris, RC;

2021

BMJ global health, (2021).6 8 10.1136/bmjgh-2021-006127.

A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars.

Olsen, AW; Rosenkrands, I; HOLLAND, MJ; Andersen, P; Follmann, F;

2021

NPJ vaccines, (2021).6 1 10.1038/s41541-021-00312-9.

Multivalent poultry vaccine development using Protein Glycan Coupling Technology.

MAURI, M; Sannasiddappa, TH; Vohra, P; Corona-Torres, R; Smith, AA; Chintoan-Uta, C; Bremner, A; TERRA, VS; ABOUELHADID, S; Stevens, MP; Grant, AJ; CUCCUI, J; WREN, BW; Glycoengineering of Veterinary Vaccines Consortium,;

2021

Microbial cell factories, (2021).20 1 10.1186/s12934-021-01682-4.